The U.S. Pentagon is implementing a new policy to screen all service members over age 30 for low testosterone and offer replacement therapy, aiming to boost combat readiness and long-term health. However, medical experts and endocrine societies have raised concerns, citing that the target population differs significantly from participants in key studies like the TRAVERSE trial, which focused on older men with existing heart conditions. These organizations caution that routine screening of asymptomatic men lacks sufficient evidence and may lead to false positives due to natural testosterone fluctuations. AI
RANK_REASON Policy announcement by a major government entity with expert criticism. [lever_c_demoted from significant: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
